JP2019526614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526614A5 JP2019526614A5 JP2019513946A JP2019513946A JP2019526614A5 JP 2019526614 A5 JP2019526614 A5 JP 2019526614A5 JP 2019513946 A JP2019513946 A JP 2019513946A JP 2019513946 A JP2019513946 A JP 2019513946A JP 2019526614 A5 JP2019526614 A5 JP 2019526614A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- acceptable salt
- pharmaceutically acceptable
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 83
- 150000003839 salts Chemical class 0.000 claims description 49
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 16
- 125000006850 spacer group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108010093965 Polymyxin B Proteins 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 8
- 239000004305 biphenyl Substances 0.000 claims description 8
- 238000010511 deprotection reaction Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229920000024 polymyxin B Polymers 0.000 claims description 8
- 229960005266 polymyxin b Drugs 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 claims description 4
- 108010028921 Lipopeptides Proteins 0.000 claims description 4
- 108010040201 Polymyxins Proteins 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- JBFNEVNUGGFPBQ-DDMCRLCFSA-N (2s,3r)-2-acetamido-3-hydroxy-n-[(2r)-3-hydroxy-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1r)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]propan-2-yl]bu Chemical compound N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(C)=O)[C@@H](C)O)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 JBFNEVNUGGFPBQ-DDMCRLCFSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-WWZHPTPQSA-N 4-O-β-D-Galactopyranosyl-D-galactopyranose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-WWZHPTPQSA-N 0.000 claims description 2
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 claims description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 claims description 2
- 108010090856 NAB 7061 peptide Proteins 0.000 claims description 2
- 108010018301 NAB 739 peptide Proteins 0.000 claims description 2
- 108010040427 NAB741 Proteins 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-SSWRVQTPSA-N colistin B Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O KNIWPHSUTGNZST-SSWRVQTPSA-N 0.000 claims description 2
- MDZVFKKBSGQKQR-YRFNEJERSA-N n-[(2s,3r)-3-hydroxy-1-[[(2r)-3-hydroxy-1-oxo-1-[[(3s,6s,9s,12s,15s,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1r)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]propan-2-yl]amino]-1-o Chemical compound N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)CCCCCCC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=CC=C1 MDZVFKKBSGQKQR-YRFNEJERSA-N 0.000 claims description 2
- YPXATFRVLZISKS-ZGVJRXJDSA-N n-[(2s,3r)-3-hydroxy-1-oxo-1-[[(2s)-1-oxo-1-[[(3s,6s,9s,12s,15s,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1r)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]butan-2-y Chemical compound N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)CCCCCCC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=CC=C1 YPXATFRVLZISKS-ZGVJRXJDSA-N 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143727A JP2022184922A (ja) | 2016-09-13 | 2022-09-09 | 新規化合物及びその治療上の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615560.8A GB201615560D0 (en) | 2016-09-13 | 2016-09-13 | Novel compounds and therapeutic uses thereof |
| GB1615560.8 | 2016-09-13 | ||
| GBGB1707076.4A GB201707076D0 (en) | 2017-05-04 | 2017-05-04 | Novel compounds and therapeutic uses thereof |
| GB1707076.4 | 2017-05-04 | ||
| PCT/GB2017/052699 WO2018051085A1 (en) | 2016-09-13 | 2017-09-13 | Novel compounds and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143727A Division JP2022184922A (ja) | 2016-09-13 | 2022-09-09 | 新規化合物及びその治療上の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526614A JP2019526614A (ja) | 2019-09-19 |
| JP2019526614A5 true JP2019526614A5 (https=) | 2020-11-05 |
| JP7185622B2 JP7185622B2 (ja) | 2022-12-07 |
Family
ID=59923474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513946A Active JP7185622B2 (ja) | 2016-09-13 | 2017-09-13 | 新規化合物及びその治療上の使用 |
| JP2022143727A Pending JP2022184922A (ja) | 2016-09-13 | 2022-09-09 | 新規化合物及びその治療上の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143727A Pending JP2022184922A (ja) | 2016-09-13 | 2022-09-09 | 新規化合物及びその治療上の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11014966B2 (https=) |
| EP (1) | EP3512544B1 (https=) |
| JP (2) | JP7185622B2 (https=) |
| KR (1) | KR102544465B1 (https=) |
| CN (1) | CN110022896B (https=) |
| AU (1) | AU2017328896B2 (https=) |
| BR (1) | BR112019004877A2 (https=) |
| DK (1) | DK3512544T3 (https=) |
| ES (1) | ES2854991T3 (https=) |
| IL (1) | IL265269B (https=) |
| MX (1) | MX2019002879A (https=) |
| WO (1) | WO2018051085A1 (https=) |
| ZA (1) | ZA201901422B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201705686D0 (en) * | 2017-04-07 | 2017-05-24 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201804098D0 (en) * | 2018-03-14 | 2018-04-25 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201904534D0 (en) * | 2019-04-01 | 2019-05-15 | Centauri Therapeutics Ltd | Novel compounds an therapeutic uses thereof |
| GB202406865D0 (en) | 2024-05-15 | 2024-06-26 | Centauri Therapeutics Ltd | Novel compounds and therapeutics uses thereof |
| WO2025236916A1 (en) * | 2024-05-16 | 2025-11-20 | Brii Biosciences, Inc. | Compositions and methods for treating infections |
| GB202410052D0 (en) * | 2024-07-10 | 2024-08-21 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| EP1594898A2 (en) * | 2003-02-06 | 2005-11-16 | Tripep AB | Glycosylated specificity exchangers |
| CA2517396A1 (en) * | 2003-02-28 | 2005-03-10 | Antigenics Inc. | Use of lectins to promote oligomerization of glycoproteins and antigenic molecules |
| BRPI1011269A2 (pt) * | 2009-05-05 | 2016-09-27 | Altermune Technologies Llc | imunidade quimicamente programável |
| CA2855916A1 (en) * | 2011-11-18 | 2013-05-23 | Novacta Biosystems Limited | Polymyxin derivatives |
| WO2016104647A1 (ja) | 2014-12-25 | 2016-06-30 | 国立大学法人大阪大学 | 糖鎖結合ワクチン抗原及び糖鎖導入剤 |
| GB201517859D0 (en) | 2015-10-08 | 2015-11-25 | Altermune Ltd | Novel compounds and therapeutic uses thereof |
-
2017
- 2017-09-13 WO PCT/GB2017/052699 patent/WO2018051085A1/en not_active Ceased
- 2017-09-13 DK DK17771531.5T patent/DK3512544T3/da active
- 2017-09-13 ES ES17771531T patent/ES2854991T3/es active Active
- 2017-09-13 EP EP17771531.5A patent/EP3512544B1/en active Active
- 2017-09-13 BR BR112019004877A patent/BR112019004877A2/pt unknown
- 2017-09-13 KR KR1020197010569A patent/KR102544465B1/ko active Active
- 2017-09-13 JP JP2019513946A patent/JP7185622B2/ja active Active
- 2017-09-13 US US16/333,219 patent/US11014966B2/en active Active
- 2017-09-13 AU AU2017328896A patent/AU2017328896B2/en active Active
- 2017-09-13 MX MX2019002879A patent/MX2019002879A/es unknown
- 2017-09-13 CN CN201780069622.1A patent/CN110022896B/zh active Active
-
2019
- 2019-03-07 ZA ZA201901422A patent/ZA201901422B/en unknown
- 2019-03-11 IL IL265269A patent/IL265269B/en unknown
-
2022
- 2022-09-09 JP JP2022143727A patent/JP2022184922A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526614A5 (https=) | ||
| Branco et al. | Materials from peptide assembly: towards the treatment of cancer and transmittable disease | |
| JP2018531287A5 (https=) | ||
| JP2020515574A (ja) | 免疫調節剤としての置換イソキノリン誘導体 | |
| UA125223C2 (uk) | СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING | |
| JP2006507265A5 (https=) | ||
| CN110831954A (zh) | 双2’-5’-rr-(3’f-a)(3’f-a)环二核苷酸化合物及其用途 | |
| EA019151B1 (ru) | Конъюгаты синтетических агонистов tlr и их применение | |
| CN109952305A (zh) | 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| Hainline et al. | Progress toward the clinical translation of bioinspired peptide and protein assemblies | |
| JP2016526540A5 (https=) | ||
| JP2019526596A5 (https=) | ||
| JP2012532136A5 (https=) | ||
| JP2016534059A5 (https=) | ||
| JP2012504133A5 (https=) | ||
| KR20070010125A (ko) | 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물 | |
| JP2010527913A5 (https=) | ||
| JP2013509389A5 (https=) | ||
| Gostaviceanu et al. | Membrane-active peptides and their potential biomedical application | |
| JP2022184922A (ja) | 新規化合物及びその治療上の使用 | |
| Hasanzadeh et al. | Silk fibroin nanoadjuvant as a promising vaccine carrier to deliver the FimH-IutA antigen for urinary tract infection | |
| CN116056765A (zh) | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 | |
| KR102446655B1 (ko) | 면역항암 보조제 | |
| JP2020535811A5 (https=) | ||
| JP2010500284A5 (https=) |